Study identifier:BCB106 (DURATION - 2)
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects with Type 2 Diabetes Mellitus Treated with Metformin
Type 2 Diabetes Mellitus
Phase 3
No
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
All
514
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: exenatide once weekly subcutaneous injection, 2.0mg, once a week Drug: placebo tablet oral tablet, once a day |
Active Comparator: 2 | Drug: sitagliptin oral tablet, 100mg, once a day Other Name: Januvia Drug: placebo once weekly subcutaneous injection, once a week |
Active Comparator: 3 | Drug: pioglitazone oral tablet, 45mg, once a day Drug: placebo once weekly subcutaneous injection, once a week |